The genetics of ovarian cancer

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 16, Issue 4, 2002, Pages 449-468

  Pharoah, Paul D P ^a   Ponder, Bruce A J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

BRCA1; BRCA2; Family history; Genetics; Risk

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DISEASE ASSOCIATION; FAMILIAL DISEASE; FAMILY HISTORY; GENE LOCUS; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MISMATCH REPAIR; MUTATION RATE; OVARY CANCER; PRIORITY JOURNAL; REVIEW; FAMILIAL CANCER; FEMALE; GENETIC PREDISPOSITION; GENETICS; OVARY TUMOR; TUMOR SUPPRESSOR GENE;

FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; OVARIAN NEOPLASMS;

EID: 0036674296     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2002.0296     Document Type: Article

References (96)

1. Stratton JF, Pharoah PDP, Smith SK et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. British Journal of Obstetrics and Gynaecology 1998; 105: 493-499.
2. Auranen A, Pukkala E, Makinen J et al. Cancer incidence in the first-degree relatives of ovarian cancer patients. British Journal of Cancer 1996; 74: 280-284.
3. Easton DF, Matthews FE, Ford D et al. Cancer mortality in relatives of women with ovarian cancer: the OPCS study. International Journal of Cancer 1996; 65: 284-294.
4. Schildkraut JM & Thompson WD. Familial ovarian cancer: a population-based case-control study. American Journal of Epidemiology 1988; 128: 456-466.
5. Sutcliffe S, Pharoah PD, Easton DF & Ponder BA. Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer. International Journal of Cancer 2000; 87: 110-117.
6. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. New England Journal of Medicine 2000; 343: 78-85.
7. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the 17 linked breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
8. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792.
9. Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genetics 1995; 11: 198-200.
10. Fitzgerald MG, MacDonald DJ, Krainer M et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. New England Journal of Medicine 1996; 334: 143-149.
11. Offit K, Gilewski T, McGuire P et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996; 347: 1643-1645.
12. Neuhausen S, Gilewski T, Norton L et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genetics 1996; 13: 126-128.
13. Thorlacius S, Olafsdottir G, Tryggvadottir L et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nature Genetics 1996; 13: 117-119.
14. Gayther SA, Pharoah PDP & Ponder BAJ. The genetics of inherited breast cancer. Journal of Mammary Gland Biology and Neoplasia 1998; 3: 365-376.
15. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. American Journal of Human Genetics 1998; 62: 676-689.
16. Gayther SA, Russell P, Harrington P et al. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. American Journal of Human Genetics 1999; 65: 1021-1029.
17. Takahashi H, Behbakht K, McGovern PE et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Research 1995; 55: 2998-3002.
18. Matsushima M, Kobayashi K, Emi M et al. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Human Molecular Genetics 1995; 4: 1953-1956.
19. Stratton JF, Gayther SA, Russell P et al. Contribution of BRCA1 mutations to ovarian cancer. New England Journal of Medicine 1997; 336: 1125-1130.
20. Rubin SC, Blackwood MA, Bandera C et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. American Journal of Obstetrics and Gynecology 1998; 178: 670-677.
21. Janezic SA, Ziogas A, Krumroy LM et al. Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Human Molecular Genetics 1999; 8: 889-897.
22. Khoo US, Ngan HY, Cheung AN et al. Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations. Human Mutation 2000; 16: 88-89.
23. van der Looij M, Szabo C, Besznyak I et al. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. International Journal of Cancer 2000; 86: 737-740.
24. Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics 2001; 68: 700-710.
25. Abeliovich D, Kaduri L, Lerer I et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. American Journal of Human Genetics 1997; 60: 505-514.
26. Beller U, Halle D, Catane R et al. High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecologic Oncology 1997; 67: 123-126.
27. Gotlieb WH, Friedman E, Bar Sade RB et al. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. Journal of the National Cancer Institute 1998; 90: 995-1000.
28. Lu KH, Cramer DW, Muto MG et al. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstetrics Gynecology 1999; 93: 34-37.
29. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. Journal of the American Medical Association 2000; 283: 2260-2265.
30. Moslehi R, Chu W, Karlan B et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi jewish women with ovarian cancer. American Journal of Human Genetics 2000; 66: 1259-1272.
31. Ramus SJ, Fishman A, Pharoah PDP et al. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. European Journal of Surgery and Oncology 2001; 27: 278-281.
32. Tonin PM, Mes Masson AM, Narod SA et al. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clinical Genetics 1999; 55: 318-324.
33. Dorum A, Hovig E, Trope C et al. Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. European Journal of Cancer 1999; 35: 779-781.
34. Ford D, Easton DF, Bishop DT et al. Risks of Cancer in BRCA1 mutation carriers. Lancet 1994; 343: 692-695.
35. Easton DF, Ford D & Bishop DT. Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. American Journal of Human Genetics 1995; 56: 265-271.
36. Hopper JL, Southey MC, Dite GS et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Cancer Epidemiology Biomarkers and Prevention 1999; 8: 741-747.
37. Antoniou AC, Gayther SA, Stratton JF et al. Risk models for familial breast and ovarian cancer. Genetics and Epidemiology 2000; 18: 173-190.
38. Thorlacius S, Struewing JP, Hartge P et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352: 1337-1339.
39. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 in a population based series of breast cancer cases. British Journal of Cancer 2000; 83: 1301-1308.
40. Warner E, Foulkes W, Goodwin P et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. Journal of the National Cancer Institute 1999; 91: 1241-1247.
41. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New England Journal of Medicine 1997; 336: 1401-1408.
42. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. Journal of the National Cancer Institute 1999; 91: 1310-1316.
43. Gayther SA, Warren W, Mazoyer S et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genetics 1995; 11: 428-433.
44. Gayther SA, Mangion J, Russell P et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genetics 1997; 15: 103-105.
45. Thompson D & Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. American Journal of Human Genetics 2001; 68: 410-419.
46. Narod SA, Goldgar D, Cannon Albright L et al. Risk modifiers in carriers of BRCA1 mutations. International Journal of Cancer 1995; 64: 394-398.
47. Johannsson O, Loman N, Borg A & Olsson H. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet 1998; 352: 1359-1360.
48. Jernstrom H, Lerman C, Ghadirian P et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999; 354: 1846-1850.
49. Brunet JS, Ghadirian P, Rebbeck TR et al. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. Journal of the National Cancer Institute 1998; 90: 761-766.
50. Narod SA, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. New England Journal of Medicine 1998; 339: 424-428.
51. Modan B, Hartge P, Hirsh-Yechezkel G et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. New England Journal of Medicine 2001; 345: 235-240.
52. Narod SA, Sun P, Ghadirian P et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001; 357: 1467-1470.
53. Krontiris TG, Devlin B, Karp DD et al. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. New England Journal of Medicine 1993; 329: 517-523.
54. Phelan CM, Rebbeck TR, Weber BL et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genetics 1996; 12: 309-311.
55. Rebbeck TR, Kantoff PW, Krithivas K et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. American Journal of Human Genetics 1999; 64: 1371-1377.
56. Levine DA & Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Research 2001; 61: 908-911.
57. Rebbeck TR, Kantoff PW, Krithivas K et al. Modification of breast cancer risk in BRCA1 mutation carriers by the A1B1 gene. American Association for Cancer Research Annual Meeting, March 1999; Philadelphia, p 194.
58. Buller RE, Anderson B, Connor JP & Robinson R. Familial ovarian cancer. Gynecologic Oncology 1993; 51: 160-166.
59. Chang J, Fryatt I, Ponder B et al. A matched control study of familial epithelial ovarian cancer: patient characteristics, response to chemotherapy and outcome. Annals of Oncology 1995; 6: 80-82.
60. Johannsson OT, Idvall I, Anderson C et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. European Journal of Cancer 1997; 33: 362-371.
61. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. New England Journal of Medicine 1996; 335: 1413-1416.
62. Pharoah PDP, Easton DF, Stockton DL et al. Survival in familial, BRCA1 and BRCA2 associated epithelial ovarian cancer. Cancer Research 1999; 59: 868-871.
63. Werness BA, Ramus SJ, Whittemore AS et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Human Pathology 2000; 31: 1420-1424.
64. Johannsson OT, Ranstam J, Borg A & Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. Journal of Clinical Oncology 1998; 16: 398-404.
65. Lee JS, Wacholder S, Struewing JP et al. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute 1999; 91: 259-263.
66. Lynch HT, Shaw MW, Magnuson CW et al. Hereditary factors in cancer. Study of two large midwestern kindreds. Archives of Internal Medicine 1966; 117: 206-212.
67. Wheeler JM, Bodmer WF & Mortensen NJ. DNA mismatch repair genes and colorectal cancer. Gut 2000; 47: 148-153.
68. Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. International Journal of Cancer 1999; 81: 214-218.
69. Stratton JF, Thompson D, Bobrow L et al. The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. American Journal of Human Genetics 1999; 65: 1725-1732.
70. Peto J, Collins N, Barfoot R et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. Journal of the National Cancer Institute 1999; 91: 943-949.
71. International SNP Map Working Group. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Natue 2001; 409: 928-933.
72. Khoury MJ. Genetic Epidemiology. In Rothman K & Greenland S (eds) Modern epidemiology, 2nd edn. Philadelphia: Lippincott-Raven, 1997.
73. Risch N & Merikangas K. The future of genetic studies of complex diseases. Science 1996; 273: 1516-1517.
74. Bryan EJ, Thomas NA, Palmer K et al. Refinement of an ovarian cancer tumour suppressor gene locus on chromosome arm 22q and mutation analysis of CYP2D6, SREBP2 and NAGA. International Journal of Cancer 2000; 87: 798-802.
75. Runnebaum IB, Tong XW, Konig R et al. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet 1995; 345: 994.
76. Lancaster JM, Brownlee HA, Wiseman RW & Taylor J. p53 polymorphism in ovarian and bladder cancer. Lancet 1995; 346: 182.
77. Campbell IG, Eccles DM, Dunn B et al. p53 polymorphism in ovarian and breast cancer. Lancet 1996; 347: 393-394.
78. Wang Gohrke S, Weikel W, Risch H et al. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. British Journal of Cancer 1999; 81: 179-183.
79. Mavridou D, Gornall R, Campbell IG & Eccles DM. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. British Journal of Cancer 1998; 77: 676-677.
80. Buller RE, Sood A, Fullenkamp C et al. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Therapy 1997; 4: 239-245.
81. Hengstler JG, Kett A, Arand M et al. Glutathione S-transferase T1 and M1 gene defects in ovarian carcinoma. Cancer Letters 1998; 130: 43-48.
82. Spurdle AB, Webb PM, Purdie DM et al. Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis 2001; 22: 67-72.
83. Spurdle AB, Webb PM, Chen X et al. Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer. International Journal of Cancer 2000; 87: 637-643.
84. Spurdle AB, Chen X, Abbazadegan M et al. CYP17 promoter polymorphism and ovarian cancer risk. International Journal of Cancer 2000; 86: 436-439.
85. Spurdle AB, Webb PM, Purdie DM et al. No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis 2001; 22: 717-721.
86. Weitzel JN, Ding S, Larson GP et al. The HRAS1 minisatellite locus and risk of ovarian cancer. Cancer Research 2000; 60: 259-261.
87. Piver MS, Baker TR, Jishi MF et al. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 1993; 71: 582-588.
88. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
89. Struewing JP, Watson P, Easton DF et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Journal of the National Cancer Institute Monographs 1995; 17: 33-35.
90. Piver MS, Jishi MF, Tsukada Y & Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993; 71: 2751-2755.
91. NIH Consensus Development Panel on Ovarian Cancer. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. Journal of the American Medical Association 1995; 273: 491-497.
92. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Journal of the American Medical Association 1997; 277: 997-1003.
93. Rebbeck TR, Levin AM, Eisen A et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. Journal of the National Cancer Institute 1999; 91: 1475-1479.
94. Bourne TH, Campbell S, Reynolds KM et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. British Medical Journal 1993; 306: 1025-1029.
95. Einhorn N, Sjovall K & Knapp RC. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstetrics and Gynecology 1992; 80: 14-18.
96. Karlan BY, Baldwin RL, Lopez-Luevanos E et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. American Journal of Obstetrics and Gynecology 1999; 180: 917-928.